MENU
+Compare
IDXG
Stock ticker: OTC
AS OF
Jul 3 closing price
Price
$0.77
Change
-$0.00 (-0.00%)
Capitalization
8.62M

IDXG stock forecast, quote, news & analysis

Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features... Show more

IDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IDXG with price predictions
Jul 03, 2025

IDXG's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IDXG turned positive on June 30, 2025. Looking at past instances where IDXG's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXG advanced for three days, in of 177 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on July 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXG as a result. In of 129 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for IDXG entered a downward trend on June 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (24.348). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.244) is also within normal values, averaging (42.660).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IDXG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 8.58B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was -0%. LDXHF experienced the highest price growth at 120%, while HSDT experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -70%. For the same stocks of the Industry, the average monthly volume growth was -54% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 72
Price Growth Rating: 59
SMR Rating: 85
Profit Risk Rating: 90
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
IDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of commercialization services to biopharmaceutical companies

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
300 Interpace Parkway
Phone
+1 855 776-6419
Employees
94
Web
https://www.interpace.com